Cellectis S.A. (EPA:ALCLS)
France · Delayed Price · Currency is EUR 3.150
-0.040 (-1.25%)
At close: Mar 13, 2026
Cellectis Market Cap
Cellectis has a market cap or net worth of €227.82 million as of March 13, 2026. Its market cap has increased by 149.31% in one year.
Market Cap
227.82M
Enterprise Value
259.03M
Revenue
70.36M
Ranking
n/a
PE Ratio
n/a
Stock Price
€3.15
Market Cap Chart
Since February 7, 2007, Cellectis's market cap has increased from 100.59M to 227.82M, an increase of 126.48%. That is a compound annual growth rate of 4.37%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 13, 2026 | 227.82M | -24.91% |
| Dec 31, 2025 | 303.40M | 158.68% |
| Dec 31, 2024 | 117.29M | -40.86% |
| Dec 29, 2023 | 198.32M | 118.98% |
| Dec 30, 2022 | 90.57M | -73.23% |
| Dec 31, 2021 | 338.35M | -67.37% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Valneva SE | 831.23M |
| MedinCell | 792.04M |
| Genfit | 446.42M |
| Transgene | 217.97M |
| Sensorion | 165.19M |
| MaaT Pharma | 134.35M |
| Innate Pharma | 126.53M |
| Adocia | 122.07M |